F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase

Jason D. Oliver, Graham E M Sibley, Nicola Beckmann, Katharine S. Dobb, Martin J. Slater, Laura McEntee, Saskia Du Pré, Joanne Livermore, Michael J. Bromley, Nathan Wiederhold, William W. Hope, Anthony J. Kennedy, Derek Law, Mike Birch

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of ≤0.06 μg/mL-greater potency than the leading antifungal classes. An investigation into the mechanism of action of F901318 found that it acts via inhibition of the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) in a fungal-specific manner. Homology modeling of Aspergillus fumigatus DHODH has identified a predicted binding mode of the inhibitor and important interacting amino acid residues. In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to the azole class of antifungals and a strain displaying an azole-resistant phenotype. F901318 is currently in late Phase 1 clinical trials, offering hope that the antifungal armamentarium can be expanded to include a class of agent with a mechanism of action distinct from currently marketed antifungals.

Original languageEnglish (US)
Pages (from-to)12809-12814
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume113
Issue number45
DOIs
StatePublished - Nov 8 2016

Fingerprint

Azoles
Aspergillus fumigatus
Pulmonary Aspergillosis
Clinical Trials, Phase I
Mycoses
Antifungal Agents
Aspergillus
Pharmaceutical Preparations
Fungi
Phenotype
Amino Acids
Enzymes
dihydroorotate dehydrogenase
Therapeutics
In Vitro Techniques
pyrimidine

Keywords

  • Antifungal drug
  • Aspergillus fumigatus
  • Dihydroorotate dehydrogenase
  • Mechanism of action

ASJC Scopus subject areas

  • General

Cite this

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. / Oliver, Jason D.; Sibley, Graham E M; Beckmann, Nicola; Dobb, Katharine S.; Slater, Martin J.; McEntee, Laura; Du Pré, Saskia; Livermore, Joanne; Bromley, Michael J.; Wiederhold, Nathan; Hope, William W.; Kennedy, Anthony J.; Law, Derek; Birch, Mike.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, No. 45, 08.11.2016, p. 12809-12814.

Research output: Contribution to journalArticle

Oliver, JD, Sibley, GEM, Beckmann, N, Dobb, KS, Slater, MJ, McEntee, L, Du Pré, S, Livermore, J, Bromley, MJ, Wiederhold, N, Hope, WW, Kennedy, AJ, Law, D & Birch, M 2016, 'F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase', Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 45, pp. 12809-12814. https://doi.org/10.1073/pnas.1608304113
Oliver, Jason D. ; Sibley, Graham E M ; Beckmann, Nicola ; Dobb, Katharine S. ; Slater, Martin J. ; McEntee, Laura ; Du Pré, Saskia ; Livermore, Joanne ; Bromley, Michael J. ; Wiederhold, Nathan ; Hope, William W. ; Kennedy, Anthony J. ; Law, Derek ; Birch, Mike. / F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. In: Proceedings of the National Academy of Sciences of the United States of America. 2016 ; Vol. 113, No. 45. pp. 12809-12814.
@article{0025b78e88f64ae6ac84b98d385f36b2,
title = "F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase",
abstract = "There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of ≤0.06 μg/mL-greater potency than the leading antifungal classes. An investigation into the mechanism of action of F901318 found that it acts via inhibition of the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) in a fungal-specific manner. Homology modeling of Aspergillus fumigatus DHODH has identified a predicted binding mode of the inhibitor and important interacting amino acid residues. In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to the azole class of antifungals and a strain displaying an azole-resistant phenotype. F901318 is currently in late Phase 1 clinical trials, offering hope that the antifungal armamentarium can be expanded to include a class of agent with a mechanism of action distinct from currently marketed antifungals.",
keywords = "Antifungal drug, Aspergillus fumigatus, Dihydroorotate dehydrogenase, Mechanism of action",
author = "Oliver, {Jason D.} and Sibley, {Graham E M} and Nicola Beckmann and Dobb, {Katharine S.} and Slater, {Martin J.} and Laura McEntee and {Du Pr{\'e}}, Saskia and Joanne Livermore and Bromley, {Michael J.} and Nathan Wiederhold and Hope, {William W.} and Kennedy, {Anthony J.} and Derek Law and Mike Birch",
year = "2016",
month = "11",
day = "8",
doi = "10.1073/pnas.1608304113",
language = "English (US)",
volume = "113",
pages = "12809--12814",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "45",

}

TY - JOUR

T1 - F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase

AU - Oliver, Jason D.

AU - Sibley, Graham E M

AU - Beckmann, Nicola

AU - Dobb, Katharine S.

AU - Slater, Martin J.

AU - McEntee, Laura

AU - Du Pré, Saskia

AU - Livermore, Joanne

AU - Bromley, Michael J.

AU - Wiederhold, Nathan

AU - Hope, William W.

AU - Kennedy, Anthony J.

AU - Law, Derek

AU - Birch, Mike

PY - 2016/11/8

Y1 - 2016/11/8

N2 - There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of ≤0.06 μg/mL-greater potency than the leading antifungal classes. An investigation into the mechanism of action of F901318 found that it acts via inhibition of the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) in a fungal-specific manner. Homology modeling of Aspergillus fumigatus DHODH has identified a predicted binding mode of the inhibitor and important interacting amino acid residues. In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to the azole class of antifungals and a strain displaying an azole-resistant phenotype. F901318 is currently in late Phase 1 clinical trials, offering hope that the antifungal armamentarium can be expanded to include a class of agent with a mechanism of action distinct from currently marketed antifungals.

AB - There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of ≤0.06 μg/mL-greater potency than the leading antifungal classes. An investigation into the mechanism of action of F901318 found that it acts via inhibition of the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) in a fungal-specific manner. Homology modeling of Aspergillus fumigatus DHODH has identified a predicted binding mode of the inhibitor and important interacting amino acid residues. In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to the azole class of antifungals and a strain displaying an azole-resistant phenotype. F901318 is currently in late Phase 1 clinical trials, offering hope that the antifungal armamentarium can be expanded to include a class of agent with a mechanism of action distinct from currently marketed antifungals.

KW - Antifungal drug

KW - Aspergillus fumigatus

KW - Dihydroorotate dehydrogenase

KW - Mechanism of action

UR - http://www.scopus.com/inward/record.url?scp=84994504615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994504615&partnerID=8YFLogxK

U2 - 10.1073/pnas.1608304113

DO - 10.1073/pnas.1608304113

M3 - Article

AN - SCOPUS:84994504615

VL - 113

SP - 12809

EP - 12814

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 45

ER -